Continuing Education Credit
8.75 CE/CME + MOC

Continuing Education Credit

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Kneed Communications. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians
Amedco LLC designates this live activity for a maximum of 8.75 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 8.75 knowledge-based CPE contact hours. NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurses
Amedco LLC designates this activity for a maximum of 8.75 ANCC contact hours.

American Board of Pathology (ABPath) MOC
This activity is registered with the American Board of Pathology Maintenance of Certification Program for Self-Assessment Module (SAM) for 8.75 credit hours.
You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Learning Objectives

Integrate multi-omics data (genomic, proteomic, metabolomic, transcriptomic) into clinical decision-making across oncology and non-oncology therapeutic areas to enhance diagnostic precision and personalize patient care.
Evaluate emerging technologies—including AI-driven decision support, liquid biopsy applications, and advanced biomarker testing—and discuss how these tools can be applied to improve outcomes for diverse patient populations.
Analyze mechanisms of tumor resistance and disease progression, and apply insights from translational research and clinical trials to optimize therapeutic strategies in precision medicine.